SEATTLE--()--Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Monday, February 25, 2012, at 9:00 a.m. ET to review fourth quarter and full year 2012 financial results.
Access to the discussion may be obtained as follows:
|Time:||9:00 a.m. ET / 6:00 a.m. PT|
|Date:||February 25, 2013|
|Dial-in:||1-877-548-9590 (domestic) or +1-720-545-0037 (international)|
|conference ID number: 95297228|
www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 95297228. The replay will be available from 12:00 p.m. ET on Monday, February 25, until 11:59 p.m. ET on Monday, March 4. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the following conferences:
- Leerink Swann Global Healthcare Conference in New York City, on February 13, 2013, at 1:30 p.m. ET
- RBC Healthcare Conference in New York City, on February 27, 2013, at 8:30 a.m. ET
- Cowen and Company Healthcare Conference in Boston, on March 5, 2013, at 10:40 a.m. ET
- Barclays Capital Global Healthcare Conference in Miami, on March 13, 2013 at 1:30 p.m. ET
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.